Sale!

CJC-1295 NO-DAC (MOD GRF 1-29) – 5mg

$42.99

5 mg per vial

0.0
Rated 0.0 out of 5
0.0 out of 5 stars (based on 0 reviews)
Excellent0%
Very good0%
Average0%
Poor0%
Terrible0%
Hurry! only 48 left in stock.
Add to Wishlist
Add to Wishlist
FREE & FAST SHIPPING
PUREST QUALITY
EXCELLENT SERVICE

Leave A Review

There are no reviews yet. Be the first one to write one.

Properties

Molecular Formula

C152H252N44O42

Molecular Weight3367.9
Monoisotopic Mass3365.8935782
Polar Area1450
Complexity7710
XLogP-10.7
Heavy Atom Count238
Hydrogen Bond Donor Count52
Hydrogen Bond Acceptor Count48
Rotatable Bond Count118
Physical AppearanceFine White Lyophilized Powder
StabilityLyophilized protein is to be stored at -20°C. It is recommended to aliquot the reconstituted (dissolved) protein into several discrete vials in order to avoid repeated freezing and thawing. Reconstituted protein can be stored at 4°C
PubChem LCSS

CJC-1295 NO-DAC (MOD GRF 1-29) Laboratory Chemical Safety Summary

Identifiers

CID56841945
CAS446262-90-4
InChIInChI=1S/C152H252N44O42/c1-22-79(15)118(194-125(214)84(20)171-135(224)107(68-115(206)207)181-124(213)81(17)169-126(215)91(155)65-87-41-45-89(201)46-42-87)147(236)189-106(66-86-34-25-24-26-35-86)141(230)196-120(85(21)200)149(238)180-99(51-54-114(158)205)132(221)190-111(72-199)145(234)185-105(67-88-43-47-90(202)48-44-88)140(229)178-96(40-33-59-168-152(164)165)128(217)177-94(37-28-30-56-154)133(222)193-117(78(13)14)146(235)187-100(60-73(3)4)134(223)170-82(18)123(212)175-97(49-52-112(156)203)130(219)183-103(63-76(9)10)138(227)191-109(70-197)143(232)172-83(19)122(211)174-95(39-32-58-167-151(162)163)127(216)176-93(36-27-29-55-153)129(218)182-102(62-75(7)8)137(226)184-101(61-74(5)6)136(225)179-98(50-53-113(157)204)131(220)186-108(69-116(208)209)142(231)195-119(80(16)23-2)148(237)188-104(64-77(11)12)139(228)192-110(71-198)144(233)173-92(121(159)210)38-31-57-166-150(160)161/h24-26, 34-35, 41-48, 73-85, 91-111, 117-120, 197-202H, 22-23, 27-33, 36-40, 49-72, 153-155H2, 1-21H3, (H2, 156, 203)(H2, 157, 204)(H2, 158, 205)(H2, 159, 210)(H, 169, 215)(H, 170, 223)(H, 171, 224)(H, 172, 232)(H, 173, 233)(H, 174, 211)(H, 175, 212)(H, 176, 216)(H, 177, 217)(H, 178, 229)(H, 179, 225)(H, 180, 238)(H, 181, 213)(H, 182, 218)(H, 183, 219)(H, 184, 226)(H, 185, 234)(H, 186, 220)(H, 187, 235)(H, 188, 237)(H, 189, 236)(H, 190, 221)(H, 191, 227)(H, 192, 228)(H, 193, 222)(H, 194, 214)(H, 195, 231)(H, 196, 230)(H, 206, 207)(H, 208, 209)(H4, 160, 161, 166)(H4, 162, 163, 167)(H4, 164, 165, 168)/t79-, 80-, 81+, 82-, 83-, 84-, 85+, 91-, 92-, 93-, 94-, 95-, 96-, 97-, 98-, 99-, 100-, 101-, 102-, 103-, 104-, 105-, 106-, 107-, 108-, 109-, 110-, 111-, 117-, 118-, 119-, 120-/m0/s1
InChIKeyXOZMWINMZMMOBR-HRDSVTNWSA-N
Isomeric SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
Canonical SMILESCCC(C)C(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(CC3=CC=C(C=C3)O)N
IUPAC Name(3S)-4-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S, 3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid

Description

Description – CJC-1295 NO-DAC

CJC-1295 NO-DAC is a synthetic peptide developed to be an analogy of growth hormone-releasing hormone (GHRH)1. The 29 amino acid sequence is derived from GRF(1-29), a naturally occurring growth hormone-releasing factor. As its name implies, CJC-1295 no DAC lacks the ‘drug affinity complex’ described below2. This structural difference infers a shorter peptide half-life than its DAC-inclusive counterpart, which elicits a GH release profile that more closely reflects what occurs in nature. CJC-1295 no DAC is reported to be a potent agent for the stimulation of pulsatile growth hormone (GH) and IGF-1 release3. These biochemical actions have been shown to result in the promotion of lean body mass, enhanced strength, increased appetite, and improved quality of sleep in animal test subjects4.

Product Comparison – CJC-1295 NO-DAC

In spite of having a similar site of action, CJC-1295 no DAC (and CJC-1295 with DAC) does not stimulate GH production using the same biochemical pathway as the popular GH secretagogue GHRP-65. In light of this observation, it has been possible for researchers to administrate CJC-1295 species and GHRP-6 concurrently in order to achieve an additive positive effect on GH release.

Drug Affinity Complex – CJC-1295 NO-DAC

The drug affinity complex (DAC) is a chemical group fixed to CJC-1295 DAC that helps the peptide escape degradation by natural enzymes. By adding a component that gives CJC-1295 an affinity for albumin2, a naturally occurring protein in blood plasma, the peptide can achieve a much longer systemic half-life.

Preference for a long or short peptide half-life depends entirely on the research application of these agents.

Synonyms:

CJC-1295; CJC-1295 no-DAC; CJC-1295 without DAC; Modified Growth Releasing Factor aminos 1-29; CJC1295 NO-DAC; Modified GRF (1-29); Mod GRF 1-29; Tetrasubstituted GRF (1-29);


Peer-Reviewed Sources:

  1. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
  2. Beals, J. M., & Shanafelt, A. B. (2006). Enhancing exposure of protein therapeutics. Drug Discovery Today: Technologies, 3(1), 87-94.
  3. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
  4. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
  5. Cordido, F., Penalva, A., Dieguez, C., & Casanueva, F. F. (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. The Journal of Clinical Endocrinology & Metabolism, 76(4), 819-823.

ALL LITERATURE, INFORMATION, AND DATA, PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

Accurate research is our priority.

Same Day Shipping

Enjoy the convenience of receiving your order swiftly. We offer same-day shipping on all orders of in-stock items placed before 12:00 pm EST.

Dedicated Service

Our dedicated team is always at your service, Ready to assist you with any customer service requests you may have. We prioritize your satisfaction and aim to provide a seamless experience.

Free Shipping

To enhance your shopping experience, We offer free shipping on all orders totaling $100 or more. Rest assured, we've got you covered!

Purist Quality

We take pride in ensuring the utmost purity of our products. Every item we offer undergoes rigorous lab testing and is certified for the highest possible purity.

Shopping cart

0
image/svg+xml

No products in the cart.

Continue Shopping